奥拉帕尼杂质58 | 848136-41-4

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 奥拉帕尼杂质58
• 英文名称: 4-[[3-(4-acetylpiperazine-1-carbonyl)-4-fluorophenyl]methyl]-2H-phthalazin-1-one
• 英文别名: 4-({3-[(4-Acetylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
• CAS: 848136-41-4
• 化学式: C₂₂H₂₁FN₄O₃
• 分子量: 408.432
• InChiKey: LKZONVZIQFMBNL-UHFFFAOYSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酸 、 1-乙酰哌嗪 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 奥拉帕尼杂质58
  参考文献：
  名称：

  4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

  摘要：

  Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy. In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2. Optimized compounds from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Compound 47 is currently undergoing clinical development for the treatment of BRCA1- and BRCA2-defective cancers.

  DOI：

  10.1021/jm8001263

文献信息

• [EN] FLUORESCENT RHODAMINE DYES WITH ENHANCED CELL PERMEABILITY<br/>[FR] COLORANTS FLUORESCENTS À BASE DE RHODAMINE À PERMÉABILITÉ CELLULAIRE AMÉLIORÉE
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2021160732A1

  公开（公告）日：2021-08-19

  The invention relates to novel fluorescent rhodamine dyes with enhanced cell permeability which are rhodamine 4´-isomers having the following general structural formula A: wherein Z is selected from O(alkyl), O(aryl), S(aryl), S(O)(alkyl), S(O)(aryl), S(O)2(alkyl), S(O)2(aryl), S(O)2(-O-alkyl), S(O)2(-O-aryl), S(O)2NH(alkyl), S(O)2NH(aryl), S(O)2N(alkyl)2, S(O)2N(aryl)2, S(O)2N(alkyl)(aryl), C(O)O(alkyl), C(O)O(aryl), C(O)(alkyl), C(O)(aryl), P(O)OH(-NH-alkyl), P(O)OH(-O-alkyl), P(O)OH(-NH-aryl), P(O)OH(-O- aryl), P(O)(-O-alkyl)2, P(O)(-NH-alkyl)2, P(O)OH(-N(alkyl)2), P(O)OH(-N(aryl)2), P(O)(-N(aryl)2)2, P(O) (-N(alkyl)2)(-N(alkyl)2), P(O)(-O-aryl)2, P(O)(-NH-aryl)2, P(O)(-O-alkyl)(-O-aryl), P(O)(-NH-alkyl)(-O-aryl), P(O)(- O-alkyl)(-NH-aryl), P(O)(-NH-alkyl)(-NH-aryl), C(O)OH, C(O)NH(alkyl), C(O)NH(aryl), CON(alkyl)2, CON(aryl)2, in particular C(O)OH, C(O)NH(alkyl), C(O)NH(aryl), CON(alkyl)2, CON(aryl)2, C(O)O(alkyl) and C(O)O(aryl), or any group which is neither Cl, NH2 or NO2 and which induces a neighboring group effect via steric, ionic or bonding interactions with the adjacent carboxyl group resulting in a shift of the equilibrium between zwitterionic form and spirolactone form towards the spirolactone form. The invention further relates to 4´-isomer derivatives and probes comprising such 4´-isomers coupled to at least one reactive group or ligand which is capable to interact with or bind to other molecules, wherein said reactive group or ligand may be coupled to the rhodamine 4´-isomer fluorophore either directly or via a linker. Another aspect of the invention relates to the use of these compounds and conjugates as labels in microscopic, spectroscopic and other imaging techniques and/or as cell permeable substances penetrating through membranes of living and fixed cells in vivo or in vitro.

  该发明涉及具有增强细胞渗透性的新型荧光罗丹明染料，其为具有以下一般结构式A的罗丹明4´-异构体：其中Z从O（烷基）、O（芳基）、S（芳基）、S（O）（烷基）、S（O）（芳基）、S（O）2（烷基）、S（O）2（芳基）、S（O）2（-O-烷基）、S（O）2（-O-芳基）、S（O）2NH（烷基）、S（O）2NH（芳基）、S（O）2N（烷基）2、S（O）2N（芳基）2、S（O）2N（烷基）（芳基）、C（O）O（烷基）、C（O）O（芳基）、C（O）（烷基）、C（O）（芳基）、P（O）OH（-NH-烷基）、P（O）OH（-O-烷基）、P（O）OH（-NH-芳基）、P（O）OH（-O-芳基）、P（O）（-O-烷基）2、P（O）（-NH-烷基）2、P（O）OH（-N（烷基）2）、P（O）OH（-N（芳基）2）、P（O）（-N（芳基）2）2、P（O）（-N（烷基）2）（-N（烷基）2）、P（O）（-O-芳基）2、P（O）（-NH-芳基）2、P（O）（-O-烷基）（-O-芳基）、P（O）（-NH-烷基）（-O-芳基）、P（O）（-O-烷基）（-NH-芳基）、P（O）（-NH-烷基）（-NH-芳基）、C（O）OH、C（O）NH（烷基）、C（O）NH（芳基）、CON（烷基）2、CON（芳基）2，特别是C（O）OH、C（O）NH（烷基）、C（O）NH（芳基）、CON（烷基）2、CON（芳基）2、C（O）O（烷基）和C（O）O（芳基），或者任何既非Cl、NH2或NO2又通过立体、离子或键合相互作用与相邻羧基引起邻基效应的基团，导致席洛内酮形式和螺内酯形式之间的平衡向螺内酯形式的转变。该发明还涉及4´-异构体衍生物和探针，其包括将这种4´-异构体偶联到至少一个能够与其他分子相互作用或结合的反应性基团或配体，其中所述反应性基团或配体可以直接或通过连接剂偶联到罗丹明4´-异构体荧光团。该发明的另一个方面涉及将这些化合物和结合物用作显微镜、光谱和其他成像技术中的标记，和/或作为穿透活体或体外固定细胞膜的细胞渗透性物质。
• PHTHALAZINONE DERIVATIVES
  申请人：Martin Niall Morrison Barr

  公开号：US20080200469A1

  公开（公告）日：2008-08-21

  Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR X or CR X R Y ; if X=NR X then n is 1 or 2 and if X=CR X R Y then n is 1; R X is selected from the group consisting of H, optionally substituted C 1-20 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R Y is selected from H, hydroxy, amino; or R X and R Y may together form a spiro-C 3-7 cycloalkyl or heterocyclyl group; R C1 and R C2 are both hydrogen, or when X is CR X R Y , R C1 , R C2 , R X and R Y , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R 1 is selected from H and halo.

  化合物的分子式为(I)：其中A和B共同表示一个可选取取代的融合芳香环；X可以是NRX或CRXRY；如果X=NRX，则n为1或2，如果X=CRXRY，则n为1；RX从以下组中选择：H，可选取代的C1-20烷基，C5-20芳基，C3-20杂环基，酰胺，硫酰胺，酯，酰基和磺酰基；RY从H，羟基，氨基中选择；或者RX和RY可以共同形成一个螺环C3-7环烷基或杂环基；RC1和RC2都是氢，或者当X为CRXRY时，RC1，RC2，RX和RY与它们连接的碳原子可以形成一个可选取取代的融合芳香环；R1从H和卤素中选择。
• Phthalazinone Derivatives
  申请人：Martin Niall Morrison Barr

  公开号：US20120010204A1

  公开（公告）日：2012-01-12

  Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR X or CR X R Y ; if X═NR X then n is 1 or 2 and if X═CR X R Y then n is 1; R X is selected from the group consisting of H, optionally substituted C 1-20 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R Y is selected from H, hydroxy, amino; or R X and R Y may together form a spiro-C 3-7 cycloalkyl or heterocyclyl group; R C1 and R C2 are both hydrogen, or when X is CR X R Y , R C1 , R C2 , R X and R Y , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R 1 is selected from H and halo.

  式(I)的化合物，其中A和B在一起表示一个可选择取代的融合芳香环；X可以是NRX或CRXRY；如果X═NRX，则n为1或2，如果X═CRXRY，则n为1；RX从以下组中选择：H，可选择取代的C1-20烷基，C5-20芳基，C3-20杂环基，酰胺，硫酰胺，酯，酰基和磺酰基；RY从H，羟基，氨基中选择；或者RX和RY可以一起形成一个螺环C3-7环烷基或杂环基；RC1和RC2都是氢，或者当X是CRXRY时，RC1，RC2，RX和RY与它们连接的碳原子一起可以形成一个可选择取代的融合芳香环；R1从H和卤素中选择。
• Radiohalide-labeled targeted diagnostics and therapeutics
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US10512700B2

  公开（公告）日：2019-12-24

  Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.

  本发明公开了式(I)的化学实体，其中 R1、R2 和 n 在本文中定义，并公开了其使用方法。这些化学实体是辐射发射体，可用作治疗癌症等的治疗剂或诊断（如成像）剂，如 PARP1 过度表达的癌症。
• RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US20170266327A1

  公开（公告）日：2017-09-21

  Disclosed are chemical entities of formula (I) wherein R 1 , R 2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.